DNA Funded vs FXIFY (2026) — Which Is Better?

The Setup

DNA Funded and FXIFY represent two different philosophies in the prop trading space. DNA Funded is an Australian broker-backed challenger launched in 2024, built directly into ASIC-regulated DNA Markets infrastructure, targeting traders who want straightforward evaluation paths with raw spreads and long time horizons. FXIFY, launched in 2023 via FXPIG broker backing, emphasizes strategy flexibility and cryptocurrency exposure, positioning itself for active traders and EA developers who need multi-instrument access and rapid scaling. Both are broker-backed (a critical credibility distinction), but they serve different trader archetypes.

Money Talk

DNA Funded's base tier is $49/month, while FXIFY starts at $59/month—a $10 difference that matters less than what you get. However, the real pricing divergence emerges with add-ons. DNA Funded offers a clean value exchange: pay the challenge fee, pass evaluation, earn 80% of profits with no hidden escalation costs. Your challenge fee refunds on your first payout, reducing effective cost substantially if you pass quickly.

FXIFY's $59/month is deceptive because optional add-ons materially increase total cost. A 90% profit split (instead of 80%) or bi-weekly payouts instead of standard cycles cost extra. Instant Funding, marketed as an advantage, is "substantially higher" in fees than challenge-based entry—FXIFY's documentation doesn't quote exact figures, which is a red flag for budget-conscious traders. DNA Funded doesn't mention Instant Funding pricing opacity. For a trader scaling to $4M capital, FXIFY's stacked add-on costs could easily push total investment $200–400 beyond the headline $59. DNA Funded's transparent $49 monthly cost is more predictable.

Winner on value: DNA Funded. Winner on flexibility if you value crypto and EAs: FXIFY, if you can absorb the add-on costs.

How Each One Actually Works

Trading Platform & Execution Speed
DNA Funded uses TradeLocker—a specialized prop-friendly platform with raw spreads from 0.0 pips and tight market connectivity. FXIFY runs on MT4/MT5 and DXTrade, the industry standard. TradeLocker's zero-pip spreads give DNA Funded a mathematical edge for scalpers; MT4/MT5 give FXIFY familiarity and third-party indicator compatibility. Advantage: DNA Funded for execution costs, FXIFY for platform ecosystem.

Instrument Catalog
DNA Funded offers 800+ CFD instruments; FXIFY has 300+. The difference matters: DNA Funded covers more forex pairs, exotics, and niche commodities. FXIFY compensates with 80+ crypto CFDs (DNA Funded excludes crypto from its Rapid challenge entirely). If your strategy touches Bitcoin or Ethereum, FXIFY is mandatory. If you trade minor forex pairs or commodities, DNA Funded's breadth wins.

EA & Automated Strategy Support
FXIFY explicitly supports EAs, martingale, grid, and news trading strategies with no restrictions. DNA Funded's documentation doesn't highlight EA compatibility; TradeLocker does support APIs and integration, but it's not front-and-center as an advantage. For EA traders, FXIFY is the clearer choice—it won't penalize you for algorithmic trading.

Evaluation Structure
DNA Funded offers 1-Phase and 2-Phase challenges with no time limits—you can trade as slowly as you want. FXIFY's 1-step, 2-step, 3-step evaluations have implicit pacing (exact time limits not disclosed here). No time pressure is significant for part-time traders or those building positions methodically. DNA Funded wins for passive, low-frequency strategies.

Payout Speed & Reliability
FXIFY guarantees 3-business-day payouts. DNA Funded doesn't quote a specific SLA in the provided specs. This matters: FXIFY's transparency on payouts reduces withdrawal friction. For traders who need capital access predictably, FXIFY's stated 3-day window is reassuring.

Broker Backing
Both are broker-backed, which is critical. DNA Markets (ASIC-regulated) is an Australian regulator—rigid, trustworthy, old-money. FXPIG is less explicitly regulated in the specs provided, making DNA Funded's ASIC status a credibility advantage, particularly for traders in regulated jurisdictions concerned about regulatory arbitrage.

Who Should Choose DNA Funded

- Traders prioritizing low execution costs and raw spreads. If you're a scalper or day trader where 5–10 pips daily matters, DNA Funded's zero-pip spreads and raw execution directly impact your bottom line.

- Long-term evaluators and patient traders. No time limits on 1-Phase and 2-Phase challenges mean you can build positions over weeks, blend discretion with longer-term conviction, or trade part-time without pressure to hit daily targets.

- Forex and commodities specialists. 800+ CFD instruments covers currency exotics, energies, and metals that 300-instrument brokers skip. If your edge is in AUDUSD, crude oil, or gold volatility, DNA Funded's breadth matches your toolbox.

- Risk-averse traders in regulated territories. DNA Markets' ASIC regulation (Australian Securities and Investments Commission) is gold-standard. If you prioritize regulatory safety over feature breadth, this matters.

Who Should Choose FXIFY

- EA and algorithmic traders. Explicit EA support, no restriction on martingale or grid strategies, and MT4/MT5 platforms mean your bot runs unencumbered. DNA Funded doesn't highlight automated strategy endorsement.

- Cryptocurrency traders. 80+ crypto CFDs and dedicated crypto trading plans—DNA Funded excludes crypto from Rapid challenges entirely. If your conviction is in altcoins, FXIFY is non-negotiable.

- Traders who need transparent payout timing. 3-business-day payouts are guaranteed and published. If capital access is mission-critical (paying bills, reinvesting quickly), this SLA beats DNA Funded's unstated payout window.

- Platform maximalists. MT4/MT5 dominance means unlimited indicators, expert advisors from third-party developers, and community plugin ecosystems. TradeLocker is newer; MT4/MT5 are battle-tested across 20+ years of trader customization.

Bottom Line

DNA Funded wins for cost-conscious traders who want raw execution, long evaluation windows, and ASIC-backed regulation—particularly those trading forex, commodities, or executing complex multi-leg strategies at scale. FXIFY wins for algorithmic traders, crypto exposure, and explicit payout reliability, accepting higher total cost for broader instrument access and strategy support. If budget is tight and you trade forex/commodities manually, DNA Funded at $49/month with zero-pip spreads is the tighter fit. If you run EAs, touch crypto, or demand MT4/MT5 ecosystem, FXIFY's $59 base (plus add-ons) is the trade-off for flexibility.